

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Lisdexamphetamine (Elvanse Adult®)
Indication under review	Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults
Policy No:	APC 124
Date of Issue:	March 2016
Review Date:	March 2019
Policy Statement: Lisdexamphetamine (Elvanse Adult®) is recommended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.	
Traffic Light Status	Amber
Key Points considered:	
<ul style="list-style-type: none"> • The APC support this treatment for shared care between the specialist and GP with treatment initiated by a specialist. • The APC were satisfied with the evidence of safety and efficacy for this treatment. • There is less potential to misuse treatment. 	
<p>Reference</p> <ol style="list-style-type: none"> 1. National Institute for Health and Care Excellence (NICE). Clinical Guideline 72. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. September 2008; last modified March 2013. http://www.nice.org.uk/guidance/cg72/resources/guidance-attention-deficit-hyperactivity-disorder-pdf 2. Shire Pharmaceutical Contracts Ltd. Elvanse Adult 30mg, 50mg, 70mg capsules, hard. Summary of product characteristics. 3. Eli Lilly and Company Ltd. Strattera 10mg, 18mg, 25mg, 40mg, 60mg, 80mg or 100mg hard capsules. Summary of product characteristics. 4. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. <i>J Clin Psychiatry</i> 2008 Sep;69(9):1364-73. 5. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. <i>CNS Spectr</i> 2009 Oct;14(10):573-85. 6. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. <i>Behav Brain Funct</i> 2010;6:34. 7. NCT00697515. Safety and efficacy workplace environment study of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit hyperactivity disorder (ADHD) www.clinicaltrials.gov 8. Brams M, Giblin J, Gasior M, Gao J, Wigal T. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. <i>Postgrad Med</i> 2011 May;123(3):99-108. 9. NCT00877487. Safety and efficacy of Vyvanse in adults with attention-deficit/hyperactivity disorder. www.clinicaltrials.gov 10. Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. <i>J Clin Psychiatry</i>. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12. 12. Weisler R, Ginsberg L, Dirks B, Deas P, Adeyi B, Adler LA. Treatment with lisdexamfetamine dimesylate improves self- and informant-rated executive function behaviors and clinician- and informant-rated ADHD symptoms in adults: data from a randomized, double-blind, placebo-controlled study. <i>J Atten Disord</i> 2014 Jan 24. 13. NCT01101022. Safety and efficacy of SPD489 on executive function behaviors in adults with attention-deficit/hyperactivity disorder (ADHD) www.clinicaltrials.gov 14. Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine Dimesylate in Adults With Attention-Deficit Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study. <i>J Clin Psychiatry</i> 2013;74(7):694-702. 15. Bolea-Alamañac B, Nutt DJ, Adamou M et al, for the Consensus Group. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> 2014:1–25 	
Date taken to APC:	2 nd March 2016
Date Ratified by MMC on Behalf of the Board:	23 rd March 2016

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only